What Is Menopause? An Honest Guide to the Biology, Symptoms, and What Helps

What's actually happening in your body during perimenopause and menopause, why the symptoms are real, and what the evidence says about HRT, gut health, and lifestyle.

Quick Summary

Menopause is clinically defined as twelve consecutive months without a menstrual period, occurring at a median age of about 51 in Western countries.^1,2 It is caused by the natural decline of ovarian hormone production, primarily oestrogen and progesterone. The transition that leads up to it, perimenopause, typically begins in the mid-to-late 40s and can last 5 to 10 years. The transition is often more symptomatic than the post-menopausal years that follow, because hormone levels fluctuate erratically rather than declining smoothly.³ Menopause affects far more than reproductive function. Bone density, cardiovascular health, metabolic function, brain function, gut microbiome composition, and skin all shift as oestrogen declines.^4,5 The most effective treatment for moderate-to-severe vasomotor symptoms remains hormone therapy (HT), particularly when initiated within 10 years of the final menstrual period in healthy women under 60, per the 2022 North American Menopause Society position statement.⁶ The 2002 Women's Health Initiative findings that drove HRT into widespread retreat were specific to one formulation (conjugated equine oestrogen plus the synthetic progestin medroxyprogesterone acetate) in women with an average age of 63, and have been substantially re-analyzed since.⁷ Lifestyle, gut health, and selected supplements play meaningful supporting roles, though none replace HRT for severe symptoms.

Key Terms

Perimenopause: The hormonal transition leading up to the final menstrual period. Typically lasts 5 to 10 years and is often the most symptomatic phase due to erratic hormone fluctuations.

Menopause: Defined retrospectively as 12 consecutive months without a menstrual period. Median age in Western countries is approximately 51.

Oestradiol (E2): The most potent and primary form of oestrogen during reproductive years. Becomes scarce post-menopause; modern body-identical HRT replaces this exact molecule.

Oestrobolome: The subset of gut bacteria capable of metabolising oestrogens via beta-glucuronidase. Influences how much circulating oestrogen the body re-absorbs through enterohepatic circulation.

Vasomotor symptoms: The medical term for hot flashes and night sweats. Affect up to 80 percent of women, with a mean duration of 7 to 10 years.

The Biology of Menopause and Perimenopause

The cleanest way to start this conversation is with the definitions. Menopause is the point in time twelve months after a woman's final menstrual period, identified retrospectively. The median age in Western countries is roughly 51 to 52, with substantial variation by ethnicity, smoking status, and genetics; globally, the median is closer to 48 to 49.¹

Menopause is caused by the natural depletion of ovarian follicles and the resulting decline in oestrogen and progesterone production. Three forms of oestrogen matter for the conversation: oestradiol (E2), the most potent and dominant form during reproductive years; oestrone (E1), which becomes the dominant post-menopausal form, partly produced in adipose tissue; and oestriol (E3), mainly produced in pregnancy. Progesterone, produced by the corpus luteum after ovulation, declines along with oestrogen and is involved in sleep regulation, anxiety modulation, and uterine lining maintenance.²

Follicle-stimulating hormone (FSH) rises during perimenopause as the brain attempts to compensate for declining ovarian function and falling inhibin B levels. FSH is a key marker of the transition, but its day-to-day variability during perimenopause means it cannot be used as a single-point diagnostic.

The biology is straightforward. The communication of the biology, historically, has not been.

Why Perimenopause Is Often the Hardest Part

Most public discussion of menopause focuses on the post-menopausal state. The phase that drives most of the felt experience is the one that comes before it.

Perimenopause typically begins in the mid-to-late 40s and lasts 5 to 10 years.³ During this window, hormone levels do not decline smoothly. They fluctuate erratically, sometimes within the same week. Oestrogen can swing high and low, sometimes higher than typical pre-menopausal levels and sometimes very low, on an unpredictable schedule. Progesterone tends to drop sooner than oestrogen, contributing to sleep disruption and mood shifts in the early transition years. Symptoms during perimenopause are frequently more intense than the post-menopausal years that follow, because the body is responding to the hormonal swings, not just the declining baseline.

This matters because many women in their mid-40s are in perimenopause without recognizing it. Brain fog, sleep disruption, mood changes, periods that become irregular, gut symptoms, and a creeping sense of feeling "off" are not always read as menopause-adjacent. They often are. If you are over 40 and have noticed your body feeling different in ways that do not have a simpler explanation, perimenopause is worth considering as part of the picture.

Beyond Hot Flashes: How Menopause Affects the Whole Body

The popular understanding of menopause is roughly: hot flashes, periods stop, mood swings, done. The clinical reality is much wider.

A symptom-frequency survey of more than 1,300 women in clinical care identified well over 80 distinct symptoms across the menopause transition.⁸ The most commonly reported were not hot flashes. They were fatigue and low energy (95 percent), memory problems (94 percent), difficulty concentrating (92 percent), and word-finding difficulty (90 percent). Hot flashes were in the top 10 but not at the top. The "34 symptoms" figure widely cited in media is a useful communication shorthand; the actual clinical picture is broader.

The systems affected by oestrogen decline include:

Bone. Bone density loss accelerates to 1 to 5 percent per year in the first 5 to 7 years after menopause, with up to 20 percent total loss possible during this window.⁹ Oestrogen suppresses osteoclast-mediated bone resorption; its absence shifts the balance toward bone breakdown. Women with serum oestradiol below 5 pg/ml have an eightfold increase in fracture risk.

Brain. Oestrogen has neuroprotective effects across multiple mechanisms, including synaptic plasticity, mitochondrial function, and anti-inflammatory signaling. The "critical window hypothesis," supported by observational data (though not yet by a definitive RCT), proposes that HRT initiated within 10 years of menopause may be neuroprotective, while late initiation may be neutral or harmful. The formulation matters: studies of conjugated equine oestrogen plus synthetic progestin have not shown the same cognitive signal as body-identical HRT.¹⁰

Cardiovascular and metabolic. Insulin sensitivity declines post-menopause; visceral fat accumulates; cardiovascular risk shifts. A meta-analysis of 17 RCTs found that hormone therapy can significantly reduce insulin resistance in post-menopausal women.¹¹ Visceral fat shifts from 5 to 8 percent of total body weight pre-menopause to 15 to 20 percent post-menopause in many women.

Vasomotor. Hot flashes and night sweats affect up to 80 percent of women. Mean duration is 7 to 10 years; more than a third experience them for over 10 years.¹²

Genitourinary. Vaginal dryness, urinary urgency, and changes in vaginal microbiome composition are common and frequently undertreated. Topical oestrogen has strong evidence for symptom relief and is generally considered low-risk even in women who cannot take systemic HRT.

Naming this range is not meant to alarm. It is meant to validate. The fatigue and the brain fog and the joint aches and the changes in mood are not "just getting older." They have a hormonal explanation. That explanation does not by itself produce a treatment plan, but it does produce permission to take the symptoms seriously.

The Gut-Menopause Connection

One of the more interesting recent threads in menopause science runs through the gut.

The oestrobolome is the subset of gut bacteria that metabolises oestrogens via the enzyme beta-glucuronidase. This enzyme reactivates conjugated (inactive) oestrogen back to its free form, which is then re-absorbed via enterohepatic circulation. The composition of the gut microbiome therefore influences how much oestrogen circulates in the body. A large observational study in a Hispanic/Latino cohort (n>1,000, mSystems) found that postmenopausal women had decreased microbial beta-glucuronidase abundance and a gut microbiome composition more similar to men's than to pre-menopausal women's, and that these changes were associated with adverse cardiometabolic outcomes.¹³

A separate human cohort study from the SWAN program (n=65, JCI Insight) found that markers of gut permeability increased measurably during the menopause transition: FABP2 by approximately 23 percent, LBP by approximately 4 percent, and sCD14 by approximately 9 percent. These changes were associated with lower bone density and higher inflammation.¹⁴ Animal models suggest oestrogen and progesterone help maintain gut barrier integrity; ovariectomy in animals increases intestinal permeability.

A 2025 systematic review and meta-analysis (39 studies, 3,187 women) found that probiotics, particularly Lactobacillus strains and especially Lactobacillus acidophilus, have positive effects on menopausal symptoms, urogenital health, bone health, and the efficacy of oestradiol and isoflavones.¹⁵ The effects are strain-specific and the trials are mostly small. The mechanistic story is clearer than the clinical proof.

The honest summary: the gut microbiome and the menopausal transition are connected, the oestrobolome is a real concept with measurable correlates, and supporting gut diversity is reasonable. The connection is not a cure for menopause symptoms and is not yet established as a primary intervention; it is a meaningful adjunct that supports a system already shifting.

WonderBiotics Probiotics for Vaginal Health and Probiotics for Gut Health are formulated with strain-level transparency (genus, species, strain designation), end-of-shelf-life CFU per strain, no proprietary blends, GMP manufacturing, and per-batch Certificates of Analysis available on request. They sit alongside the foundational levers of perimenopause and menopause management (sleep, movement, dietary fiber, protein, stress management, and where appropriate, HRT), not in place of them. Current human evidence does not support framing any consumer probiotic as a treatment for menopausal symptoms specifically.

HRT, the WHI Story, and the Modern Evidence

Hormone therapy is the single most consequential conversation in menopause care, and it has been distorted for two decades by the misapplication of one large trial.

The 2002 Women's Health Initiative (WHI) trial of hormone therapy was stopped early after finding increases in breast cancer (26 percent), stroke (41 percent), and heart attack (29 percent) in women taking the combination of conjugated equine oestrogen (CEE) and the synthetic progestin medroxyprogesterone acetate (MPA).⁷ The headline findings drove millions of women off HRT and made primary care physicians cautious about prescribing it.

The findings were specific in ways the headline did not capture. The average age of WHI participants was 63, well past the typical age of menopause and a decade outside the window in which HRT is most beneficial. The formulation was CEE+MPA, not the body-identical formulations that have largely replaced it in modern care. Subsequent re-analyses showed that risks were substantially overstated for younger women closer to menopause onset; that oestrogen-only therapy was associated with a reduced risk of breast cancer in some groups; and that absolute risks for most outcomes are rare in younger, healthy women (fewer than 10 events per 10,000 per year).⁷

The 2022 North American Menopause Society Hormone Therapy Position Statement concludes that "the benefits of hormone therapy outweigh the risks for most healthy symptomatic women who are aged younger than 60 years and within 10 years of menopause onset."⁶

A second important distinction is between modern body-identical HRT (transdermal oestradiol plus oral micronised progesterone, regulated under standard pharmaceutical pathways) and compounded bioidentical HRT (cBHRT), which is custom-mixed by specialty pharmacies and lacks the same regulatory oversight and safety data. Observational evidence and some RCT data suggest that micronised progesterone is associated with lower breast cancer risk and fewer side effects than MPA. The British Menopause Society, while supportive of regulated body-identical HRT, has been explicit that compounded BHRT is not supported by the same evidence.¹⁶

What this means in practice. HRT is not safe for everyone. Contraindications include oestrogen-sensitive cancers, prior cardiovascular events, and inherited thromboembolic disease. HRT also is not the only option for managing symptoms. But the current evidence position is that HRT is the most effective treatment for moderate-to-severe vasomotor symptoms, that the modern formulations are not the formulation tested in WHI, and that the decision is an individual conversation with a clinician who knows the specific person, not a category-wide prohibition based on a 23-year-old trial in a different population.

Lifestyle and Natural Supports That Actually Help

A short list of lifestyle and supplement strategies with reasonable evidence behind them.

Exercise, particularly resistance training. A meta-analysis of 24 RCTs (n=2,236) found that combined exercise and adequate nutrition produces measurable benefits to bone mineral density in post-menopausal women.¹⁷ Resistance training is particularly important for preserving muscle mass and metabolic rate during the transition.

Adequate magnesium. Observational data associate lower magnesium intake with lower bone mineral density and higher fracture risk in post-menopausal women. A 2-year intervention study found magnesium therapy increased bone density in 71 percent of patients and was associated with reduced fractures.¹⁸ Magnesium is also associated with sleep quality and modest anxiety improvement, though menopause-specific RCT evidence on those outcomes is more limited.

Soy isoflavones, with the equol caveat. Soy isoflavones (primarily genistein and daidzein) bind to oestrogen receptors and have modest evidence for reducing hot flash frequency in some populations. Efficacy depends substantially on the gut microbiome's ability to convert daidzein to equol, a metabolite with higher oestrogenic activity. More than half of people cannot produce equol, which makes response highly individual. The NAMS 2023 nonhormone position statement rates isoflavones at Level II evidence (limited or inconsistent) and does not position them as equivalent to HRT.^19,20

Dietary fiber and microbiome diversity. A diverse, fiber-rich diet supports overall microbiome health and may indirectly support oestrogen metabolism via the oestrobolome. The clinical evidence for specific symptom outcomes is limited, but the broader benefits of fiber for gut and metabolic health are well-established.

Sleep, stress, and the basics. Sleep deprivation worsens almost every menopause symptom; stress amplifies hormonal fluctuations; alcohol is a frequent vasomotor trigger. None of this is novel. All of it matters.

For severe vasomotor symptoms, the lifestyle interventions above are best understood as supportive rather than substitutive for hormone therapy. They are the right starting point for many women, but they are not the right ending point for women whose symptoms are interfering with daily function. That is a clinician conversation.

Practical Takeaways

A short list of actions and principles, calibrated to where you are with the conversation.

• If you suspect you might be in perimenopause. Symptoms in your mid-40s that do not have a simpler explanation are worth taking seriously. Track them. Bring the list to a clinician who knows the menopause transition.
• If you are weighing HRT. The 2002 WHI study tested a specific formulation in women with an average age of 63. Modern body-identical HRT (transdermal oestradiol plus oral micronised progesterone) in healthy women under 60 within 10 years of menopause has a meaningfully different benefit-risk profile, per NAMS 2022. The decision is an individual conversation, not a category-wide prohibition.
• If you are interested in natural support. Resistance training and adequate protein for bone and muscle. Magnesium if intake is low. Soy isoflavones if you are an equol producer (which most people do not know about themselves; a brief trial may be informative). Dietary fiber for microbiome diversity. None replaces HRT for severe symptoms.
• If you are paying attention to gut health. The oestrobolome is a real connection, and supporting gut microbiome diversity is reasonable as an adjunct. Probiotic evidence for menopause symptoms is emerging and strain-specific; treat any product as supportive, not curative.
• Find a clinician who knows menopause. NAMS-credentialed providers, GPs with menopause specialty training, and women's-health practitioners with menopause focus are all reasonable starting points. Many primary care physicians did not receive substantive menopause training; the gap is real, not imagined.

The Bigger Picture

Menopause is not a disease, and treating it as one has produced decades of either dismissive minimization ("it's just hot flashes") or overcorrected medicalization ("you need this supplement"). The honest middle is that menopause is a natural biological transition that affects most major body systems, that the symptoms are real, and that the options for managing them are wider than either side of the public conversation usually admits.

Perimenopause is often the hardest part. Hot flashes are not the most common symptom. The 2002 WHI study was specific in ways that the headlines never captured. Body-identical HRT is not the same as compounded bioidentical hormones. Gut health and lifestyle matter, as adjuncts and not replacements. The most useful next step is rarely a single product. It is usually a clinician who has time, a few well-chosen lifestyle changes, and the patience to let the transition unfold without pretending it is something it is not.

Related Reading

• For an evidence-based review of supplements specifically marketed for menopause, read The Complete Guide to Menopause Supplements.
• For the broader hormonal-transition framing in midlife, see Second Puberty for Women.
• For the cortisol-and-visceral-fat angle (a frequent perimenopause concern), read Belly Fat Explained: Why Visceral Fat Is the Real Metabolic Story.
• For the most-studied vaginal-health probiotic strain, see Lactobacillus crispatus Supplements.
• For an evidence-based look at vitamin claims for vaginal health, read The Truth About Vitamins for Vaginal Health.

References

1. World Health Organization. Menopause Fact Sheet. 2024. https://www.who.int/news-room/fact-sheets/detail/menopause
2. NIH / StatPearls. Menopause. NCBI Bookshelf. 2023. https://www.ncbi.nlm.nih.gov/books/NBK507826/
3. American Society for Reproductive Medicine. Perimenopause Fact Sheet. https://www.reproductivefacts.org/news-and-publications/fact-sheets-and-info-booklets/perimenopause/
4. Davis SR, et al. Menopause and the Cardiovascular System (clinical review). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/21841-perimenopause
5. El Khoudary SR, et al. Cardiovascular Fat, Menopause, and Sex Hormones in Women (SWAN Cardiovascular Fat Ancillary Study). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4570161/
6. The North American Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause. 2022. https://pubmed.ncbi.nlm.nih.gov/35797481/
7. Stuenkel CA, et al. Re-analysis and clinical context of the Women's Health Initiative hormone therapy trials. PMC / clinical perspectives. https://pmc.ncbi.nlm.nih.gov/articles/PMC10146299/
8. Newson Health Research and Education / Newson L. Symptom-frequency survey of clinic patients (1,352 new patients, Balance app data). Newson Health. 2025. https://www.newsonhealth.co.uk/research/
9. Khosla S, et al. Postmenopausal Osteoporosis: pathophysiology and management. PMC. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10000443/
10. Maki PM, Henderson VW. The Critical Window Hypothesis for Estrogen Therapy and Cognitive Function. Menopause / PMC. 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3620216/
11. Salpeter SR, et al. Meta-analysis: hormone therapy and insulin resistance in post-menopausal women. The Menopause Society. 2024. https://menopause.org/professional-resources/research-and-publications
12. Avis NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition (SWAN). JAMA Internal Medicine. 2015. https://pubmed.ncbi.nlm.nih.gov/25686030/
13. Peters BA, et al. Menopause Is Associated with an Altered Gut Microbiome and Estrobolome. mSystems. 2022. https://journals.asm.org/doi/10.1128/msystems.00273-22
14. Shieh A, et al. Gut permeability, inflammation, and bone density across the menopause transition. JCI Insight. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7098720/
15. Liaquat M, et al. The gut microbiota in menopause: Is there a role for prebiotic and probiotic solutions? Systematic review and meta-analysis. SAGE / PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12209548/
16. British Menopause Society. Bioidentical HRT consensus statement. 2026. https://thebms.org.uk/publications/consensus-statements/bioidentical-hrt/
17. Daly RM, et al. Combined exercise and adequate nutrition for bone mineral density in post-menopausal women: meta-analysis of 24 RCTs (n=2,236). 2025. https://pubmed.ncbi.nlm.nih.gov/
18. Stendig-Lindberg G, et al. Magnesium supplementation and bone density in post-menopausal women: 2-year intervention study. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC2206233/
19. Chen MN, et al. Soy isoflavone supplementation for hot flushes: systematic review and equol-producer status. PMC. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9032614/
20. The North American Menopause Society. The 2023 Nonhormone Therapy Position Statement. Menopause. 2023. https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf